Clinical Trials

Date: 2018-04-23

Type of information: Presentation of results at a congress

phase: preclinical

Announcement: presentation of results at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting

Company: Melinta Therapeutics (USA - CT)

Product: RX-P2382

Action mechanism:

antibiotic. RX-P2382 is an advanced lead investigational compound from the newly developed pyrrolocytosine class. Pyrrolocytosines were specifically designed by Melinta to target previously untapped binding sites on bacterial ribosomes and optimized for activity against today’s “superbugs”.

Disease:

Therapeutic area: Infectious diseases

Country:

Trial details:

Latest news:

• On April 23, 2018, Melinta Therapeutics presented findings at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting highlighting data for RX-P2382, an advanced lead investigational compound from the newly developed pyrrolocytosine class.
As reported, RX-P2382 demonstrated strong in vitro activity against all ESKAPE pathogens tested, including extremely-drug- and multidrug-resistant isolates of Escherichia coli (MIC90 0.25-0.5 ?g/mL), Klebsiella pneumoniae (0.125-1 ?g/mL), Pseudomonas aeruginosa (2-8 ?g/mL) and Acinetobacter baumannii (0.5-2 ?g/mL); vancomycin-resistant Enterococci (0.06-1 ?g/mL) and Staphylococcus aureus (0.06-1 ?g/mL); ciprofloxacin-resistant Neisseria gonorrhoeae (0.03-0.25 ?g/mL); and carbapenem-resistant Enterobacteriaceae (0.25-2 ?g/mL). In addition, RX-P2382 demonstrated efficacy in murine models of infection, including kidney, skin and respiratory infections - as well as peritonitis - caused by S. aureus, K. pneumoniae, S. pneumoniae and E. coli.
Paper Poster Session (PS006) - Progress in the ESKAPE Pathogen Program: the in vitro profile of an advanced lead, RX-P2382.
Paper Poster Session (PS009) - Progress in the ESKAPE Pathogen Program: the exploratory in vivo toxicological profile of an advanced lead, RX-P2382.
Oral Session (OS046) - Progress in the ESKAPE Pathogen Program: the in vivo profile of an advanced lead, RX-P2382.